PARAMETERS OF LIPID METABOLISM AND SEVERITY OF LIVER STEATOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ON THE BACKGROUND OF HYPERTENSION DEPENDING ON THE STATUS OF CARBOHYDRATE METABOLISM

О. Babak, A. Bashkirova

Abstract


The aim of the study was to establish relationships between the parameters of lipid metabolism, the severity of liver steatosis and the concentration of endothelial lipase (EL) serum levels depending on the state of carbohydrate metabolism and the presence of type 2 diabetes .

60 patients with non-alcoholic fatty liver disease (NAFLD) on the background of hypertension and overweight have been examined. The distribution of the examined patients was carried out in the following groups: group 1 - patients with hypertension without an increase in NAFLD liver fat score normal weight  (n = 8); Group 2 - with hypertension without increse in NAFLD liver fat score with overweight (n = 8); group 3 - with liver steatosis without type 2 diabetes (n = 10); group 4 - with liver steatosis and type 2 diabetes (n = 10); group 5 - with laboratory signs of steatohepatitis without type 2 diabetes (n = 16); group 6 - with laboratory signs of steatohepatitis and type 2 diabetes (n = 8). All patients were divided with accordance of age and sex. The control group consisted of 20 healthy individuals.

All patients with NAFLD on the background of hypertension and the presence of type 2 diabetes had significantly (p <0.001) higher hyperinsulinism (32.27 + 4.71 vs. 20.75 + 9.5 mkU/ml) and significantly (p <0.001) increased values of insulin resistance index HOMA-IR (9.52 + 4.21 against 4.76 + 2.23 U), which testifies in favour of type 2 diabetes.

In all patients with NAFLD on the background of hypertension, there are proatherogenic changes in lipid status, the presence of which is exacerbated with obesity and the severity of steatosis. It is most evident in patients with steatohepatitis in combination with type 2 diabetes.

The level of EL is significantly higher in patients with steatosis, regardless of the presence of diabetes and with steatohepatitis without diabetes compared with controls and patients with hypertension and normal weight. Significantly high levels of endothelial lipase were found in patients with steatohepatitis and diabetes. Correlation analysis between the HbA1c and EL levels showed a reliable direct relationship between the parameters.

So the level of EL in patients with hypertension in combination with the severity of liver steatosis is significant relative to atherosclerotic vascular lesions and prognostic as the occurrence of cardiovascular complications.

Keywords: NAFLD, hypertension, type 2 diabetes, endothelial lipase, insulin resistance

 


Full Text:

PDF

References


Cheah, M.C. (2017). Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol, 5(3), 261-271.

Barritt, A.S. 4th. (2017). Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials, no. 61, 33-38.

Karim, M.F. (2015). Non-alcoholic Fatty Liver Disease (NAFLD)--A Review. Mymensingh Med J, 24(4), 873-880.

Marino, L. (2015). Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol, 21(39), 76-77.

Rau, M. (2015). Non-alcoholic fatty liver disease (NAFLD). Dtsch Med Wochenschr, 140(14), 5-6.

Ogunsina, K. (2018). Association between life-course socio-economic status and prevalence of cardio-metabolic risk ractors in five middle-income countries. J Glob Health, 8(2), 102-123.

Liu, H. (2014). Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol, 20(26), 8407-8415.

Vanjiappan, S. (2018). Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. Diabetes Metab Syndr, 12(4), 479-482.

Gastaldelli, A. (2017). Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD. Clin Sci (Lond), 131(22), 2701-2704.

Chen, Z. (2017). A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease. Lipids Health Dis, 16(1), 203-204.

Karajamaki, A.J. (2017). Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes. Metabolism, no. 66, 55-63.

Gummesson, A. (2018). Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjects. PLoS One, 13(8), 202-206.

Golabi, P. (2018). Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine (Baltimore), 97(13), 214-216.

Madan, S.A. (2017). Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: meta-analysis. Eur J Gastroenterol Hepatol, 27(11), 1237-1248.

DiMarco, D.M. (2015). The regulation of reverse cholesterol transport and cellular cholesterol homeostasis by MicroRNAs. Biology, 4(3), 494–511.

Schilcher, I. (2017). Impact of Endothelial Lipase on Cholesterol Efflux Capacity of Serum and High-density Lipoprotein. Sci Rep, 7(1), 12485.

Takiguchi, S. (2018). Hepatic Overexpression of Endothelial Lipase Lowers High-Density Lipoprotein but Maintains Reverse Cholesterol Transport in Mice: Role of Scavenger Receptor Class B Type I/ATP-Binding Cassette Transporter A1-Dependent Pathways. Arterioscler Thromb Vasc Biol, 38(7), 1454-1467.

Chalasani, N. (2016). The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, no. 55, 2005-2023.

European Association for the Study of the Liver. (2016). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obesity facts, 9(2), 65-90.

Mancia, G. (2013). ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood pressure, 22(4), 193-278.

Vanjiappan, S. (2018). Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease. Diabetes Metab Syndr, 12(4), 479-482.




DOI: https://doi.org/10.26886/2414-634X.8(27)2018.4

Refbacks

  • There are currently no refbacks.